Presbia Revenue and Competitors
Estimated Revenue & Valuation
- Presbia's estimated annual revenue is currently $5.3M per year.
- Presbia's estimated revenue per employee is $251,000
Employee Data
- Presbia has 21 Employees.
- Presbia grew their employee count by -25% last year.
Presbia's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Manufacturing Manager | Reveal Email/Phone |
2 | Executive chairman & CEO | Reveal Email/Phone |
Presbia Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is Presbia?
Presbia is a medical device company focused on the development of the presbyopia-correcting Presbia Flexivue Microlens™ – an innovative solution for the common age-related loss of the ability to read or focus on near objects. The 3mm diameter lens is implanted in a corneal pocket created by a femtosecond laser.
keywords:N/A
N/A
Total Funding
21
Number of Employees
$5.3M
Revenue (est)
-25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Presbia News
Presbia. Geographically, the resulting regions, as well as the national/local markets registered below, are thoroughly investigated: North America (United...
Neoptics; ReVision Optics; AcuFocus; Presbia; KeraMed; Powervision; Cornea Research Foundation of America; Ocular Systems; Cornea Biosciences; DIOPTEX; SMR...
Presbyopia Correction Devices Market Size, Scope And Forecast | Leading Players AcuFocus, Refocus, Presbia, AcuFocus.
Other Companies in Irvine
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.1M | 21 | N/A | N/A |
#2 | $4M | 21 | -34% | N/A |
#3 | $2.1M | 21 | -22% | N/A |
#4 | $3M | 21 | -12% | N/A |
#5 | $3.3M | 21 | -12% | N/A |